APOE and Alzheimer disease: Prospective studies with galantamine in large samples of patients in Europe [145] and in USA [146] showed no effect of APOE genotypes on drug efficacy, but a retrospective study with a small number of AD cases in Croatia showed the intriguing result of 71% responders to galantamine treatment among APOE-4 homozygotes [147].